CRC (Colorectal Cancer)Phase 3NCT07284849

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

A Phase 3 study testing INCA33890, Bevacizumab and FOLFOX in people with CRC (Colorectal Cancer), run by Incyte Corporation at 297 sites in 22 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts

Official record

Search all trials

Trial summary

The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer. Read more about this study

Who is it for?: Ages 18 years and older
Conditions the study is for: CRC (Colorectal Cancer)
What is being tested?: INCA33890, Bevacizumab and FOLFOX
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 700 participants
Where: 297 sitesin 22 countries
Study dates: 5 Mar 2026to 28 Sep 2029
Phase: Phase 3
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Stage IV colorectal adenocarcinoma not amenable to curative resection.
No prior systemic treatment for unresectable or metastatic disease. Participants who received adjuvant or neoadjuvant therapy may enroll if there was no recurrence within 12 months of the end of treatment.
Measurable disease per RECIST v1.1.
ECOG performance status of 0 or 1.
Adequate organ function determined by laboratory results.

Who cannot join

MSI-H/dMMR per historical data in the medical record.
BRAF V600E mutation per historical data in the medical record.
Untreated and/or progressing CNS metastases.
History of other malignancy within 2 years.
Treatment with an anti-PD-(L)1 or other immune checkpoint inhibitor for any indication within the last 3 years.
Active autoimmune disease that has required systemic treatment in the past 2 years.

Show all 9Show fewer

Significant concurrent and/or uncontrolled medical condition.
History of organ transplant, including allogeneic stem cell transplantation.
Other protocol-defined inclusion/exclusion criteria apply.

Trial locations and contacts

297 sites in 22 countries. Contact the study team or a site near you to ask about taking part.

Incyte Corporation Call Center (US) contact

1.855.463.3463

medinfo@incyte.com

Incyte Corporation Call Center (ex-US) contact

+800 00027423

eumedinfo@incyte.com

Country

City, postcode or hospital

Sites recruiting now only

297 sites in 22 countries

United States78 sites, 78 recruiting

Trinity Health St Joseph Mercy Ann Arbor
Ann Arbor, Michigan, 48197
Recruiting
Thedacare Medical Oncology
Appleton, Wisconsin, 54911
Recruiting
Messino Cancer Center
Asheville, North Carolina, 28806
Recruiting
Sarah Cannon Research Institute Scri Oncology Partners
Aurora, Colorado, 80012
Recruiting
Ascension Seton Spclty Care Ctr
Austin, Texas, 78712
Recruiting
Texas Oncology
Austin, Texas, 78745
Recruiting
Saint Agnes Hospital
Baltimore, Maryland, 21229-5201
Recruiting
Cancer Center For Blood Disorders A Division of American Oncology Partners P.A
Bethesda, Maryland, 20817
Recruiting
St Lukes Mountain States Tumor Institute Msti Boise
Boise, Idaho, 83712
Not yet recruiting
Massachusetts General Hospital
Boston, Massachusetts, 02114
Not yet recruiting
Sarah Cannon Research Institute Scri Oncology Partners
Brandywine, Maryland, 20613
Recruiting
Sih Cancer Institute
Carterville, Illinois, 62918
Recruiting
The University of North Carolina At Chapel Hill
Chapel Hill, North Carolina, 27514
Recruiting
Vandalia Health Charleston Area Medical Center
Charleston, West Virginia, 25304
Not yet recruiting
Oncology Specialists of Charlotte
Charlotte, North Carolina, 28210
Recruiting
University of Virginia Medical Center
Charlottesville, Virginia, 22908
Not yet recruiting
University of Illinois Cancer Center
Chicago, Illinois, 60612
Recruiting
University of Cincinnati Cancer Institute
Cincinnati, Ohio, 45219
Recruiting
Case Comprehensive Cancer Center
Cleveland, Ohio, 44106
Not yet recruiting
Missouri Cancer Associates
Columbia, Missouri, 65201
Recruiting
Ohio State University-Arthur G James Comprehensive Cancer Center
Columbus, Ohio, 43210
Recruiting
Ohio Health
Columbus, Ohio, 43214
Not yet recruiting
Zangmeister Center
Columbus, Ohio, 43219
Not yet recruiting
University of Texas Southwestern Medical Center
Dallas, Texas, 75235
Not yet recruiting
Total Health Center
Decatur, Georgia, 30034
Not yet recruiting
Henry Ford Hospital
Detroit, Michigan, 48202
Not yet recruiting
Alliance Cancer Specialists
Doylestown, Pennsylvania, 18901
Recruiting
Alexian Brothers Medical Center
Elk Grove Village, Illinois, 60007
Not yet recruiting
Endeavor Health
Evanston, Illinois, 60201
Recruiting
Florida Oncology & Hematology
Fort Myers, Florida, 33912
Recruiting
Memorial Care Orange Coast Medical Center
Fountain Valley, California, 92708
Recruiting
Mary Washington Healthcare
Fredericksburg, Virginia, 22405
Not yet recruiting
Hematology Oncology Associates of Fredericksburg Admin
Fredericksburg, Virginia, 22408
Recruiting
Providence Medical Foundation
Fullerton, California, 92835
Recruiting
University of Florida Health
Gainesville, Florida, 32610
Recruiting
Hartford Hospital
Hartford, Connecticut, 06102
Not yet recruiting
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033
Not yet recruiting
University of Hawaii Cancer Center
Honolulu, Hawaii, 96813-2402
Not yet recruiting
Md Anderson Cancer Center
Houston, Texas, 77030
Recruiting
Community Health Network, Inc.
Indianapolis, Indiana, 46250
Recruiting
Hematology Oncology of Indiana
Indianapolis, Indiana, 46260
Recruiting
University of Iowa Hospital and Clinics
Iowa City, Iowa, 52242
Not yet recruiting
Saint Luke'S Hospital of Kansas City
Kansas City, Missouri, 64111
Recruiting
Midamerica Cancer Care
Kansas City, Missouri, 64121
Recruiting
Provision Center For Biomedical Research
Knoxville, Tennessee, 37909
Recruiting
Piedmont Cancer Institute
Locust Grove, Georgia, 30248
Recruiting
Cancer & Blood Research Center
Los Alamitos, California, 90720
Recruiting
University of California Los Angeles Health
Los Angeles, California, 90095
Not yet recruiting
Taylor Cancer Research Center
Maumee, Ohio, 43537
Recruiting
Sylvester Comprehensive Cancer Center
Miami, Florida, 33136
Recruiting
Mitchell Cancer Institute
Mobile, Alabama, 36604
Not yet recruiting
West Virginia University Cancer Institute
Morgantown, West Virginia, 26506
Recruiting
Morristown Medical Center
Morristown, New Jersey, 07960
Recruiting
Icahn School of Medicine At Mount Sinai
New York, New York, 10019
Not yet recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
Not yet recruiting
Vista Oncology Inc Ps
Olympia, Washington, 98506
Not yet recruiting
Advent Health
Orlando, Florida, 32804
Not yet recruiting
Orlando Health Cancer Institute Downtown Orlando
Orlando, Florida, 32806
Not yet recruiting
Ascension Sacred Heart Pensacola
Pensacola, Florida, 32504
Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
Not yet recruiting
Allegheny General Hospital Cancer Institute
Pittsburgh, Pennsylvania, 15212
Recruiting
Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232
Recruiting
Presbyterian Rust Medical Center
Rio Rancho, New Mexico, 87124
Recruiting
Oncura Health
Sacramento, California, 94204
Recruiting
Virginia Mason Medical Center
Seattle, Washington, 98101
Not yet recruiting
Ny Cancer and Blood Specialists
Shirley, New York, 11967
Recruiting
Avera Cancer Institute
Sioux Falls, South Dakota, 57105
Recruiting
Springfield Clinic
Springfield, Illinois, 62703
Recruiting
Oncology Hematology Associates
Springfield, Missouri, 65807
Recruiting
Washington University School of Medicine
St Louis, Missouri, 63110
Recruiting
Tampa General Hospital-Cancer Institute
Tampa, Florida, 33606
Not yet recruiting
Baylor Scott & White Health
Temple, Texas, 76508
Not yet recruiting
Montefiore Medical Center
The Bronx, New York, 10461
Not yet recruiting
The University of Arizona Cancer Center
Tucson, Arizona, 85719
Recruiting
Roche Tissue Diagnostics, Companion Diagnostics
Tucson, Arizona, 85755
Recruiting
George Washington University
Washington D.C., District of Columbia, 20037
Not yet recruiting
Shenandoah Oncology
Winchester, Virginia, 22601
Recruiting
Cancer Care Associates of York
York, Pennsylvania, 17403
Recruiting

Other trials in United States

China29 sites, 29 recruiting

Peking University First Hospital
Beijing, 100034
Not yet recruiting
Beijing Friendship Hospital, Capital Medical University
Beijing, 100050
Not yet recruiting
Xiangya Hospital Central South University
Changsha, 410013
Not yet recruiting
Sichuan Cancer Hospital
Chengdu, 610041
Not yet recruiting
Chongqing University Cancer Hospital
Chongqing, 400030
Not yet recruiting
The First People'S Hospital of Foshan
Foshan, 528000
Not yet recruiting
Fujian Medical University Union Hospital
Fuzhou, 350001
Not yet recruiting
Sun Yat-Sen University Cancer Center
Guangzhou, 510060
Not yet recruiting
The Sixth Affiliated Hospital of Sun Yat-Sen University
Guangzhou, 510080
Not yet recruiting
Zhujiang Hospital of Southern Medical University
Guangzhou, 510280
Not yet recruiting
The First Affiliated Hospital of Zhejiang University
Hangzhou, 310009
Not yet recruiting
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, 310009
Not yet recruiting
University of Science and Technology of China-First Affiliated Hospital (Anhui Provincial Hospital)
Hefei, 230001
Not yet recruiting
Inner Mongolia People'S Hospital
Hohhot, 10017
Not yet recruiting
Jinan Central Hospital
Jinan, 250013
Not yet recruiting
Affiliated Hospital of Jining Medical University
Jining, 272029
Not yet recruiting
The First Affiliated Hospital of Jinzhou Medical University
Jinzhou, 121001
Not yet recruiting
The First Hospital of Lanzhou University
Lanzhou, 730000
Not yet recruiting
Meizhou Peoples Hospital
Meizhou, 514031
Not yet recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, 330209
Not yet recruiting
Guangxi Medical University Affiliated Tumor Hospital
Nanning, 530021
Not yet recruiting
Zhongshan Hospital Fudan University
Shanghai, 200032
Not yet recruiting
Fudan University Shanghai Cancer Center
Shanghai, 200120
Not yet recruiting
The Second Hospital of Hebei Medical University
Shijiazhuang, 50000
Not yet recruiting
Tianjin Medical University Cancer Institute Hospital
Tianjin, 300060
Not yet recruiting
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, 00000
Not yet recruiting
Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, 430022
Not yet recruiting
Hubei Cancer Hospital
Wuhan, 430079
Not yet recruiting
Shaanxi Provincial People'S Hospital
Xi'an, 710068
Not yet recruiting

Other trials in China

Italy17 sites, 17 recruiting

Azienda Ospedaliero Universitaria Delle Marche
Ancona, 60020
Recruiting
Irccs Centro Di Riferimento Oncologico
Aviano, 33081
Not yet recruiting
Istituto Tumori Giovanni Paolo Ii Irccs Ospedale Oncologico Bari
Bari, 70124
Recruiting
Fondazione Poliambulanza Istituto Ospedaliero
Brescia, 25124
Recruiting
Istituto Di Candiolo Fondazione Del Piemonte Per L'Oncologia - Irccs
Candiolo, 10060
Recruiting
Azienda Ospedaliera Di Rilievo Nazionale E Di Alta Specializzazione Garibaldi
Catania, 95122
Not yet recruiting
Comitato Etico Fondazione Irccs Istituto Nazionale Dei Tumori Milano
Milan, 20133
Recruiting
Asst Grande Ospedale Metropolitano Niguarda
Milan, 20162
Recruiting
Azienda Ospedaliera Universitaria- Università Degli Studi Della Campania "Luigi Vanvitelli"
Naples, 80131
Recruiting
Iov - Istituto Oncologico Veneto Irccs
Padova, 35128
Recruiting
Azienda Ospedaliero Universitaria Pisana - Ospedale S. Chiara
Pisa, 56126
Recruiting
Ospedale Santa Maria Delle Croci
Ravenna, 48121
Recruiting
Arcispedale S. Maria Nuova Azienda Ospedaliera Di Reggio Emilia
Reggio Emilia, 42121
Recruiting
Azienda Ospedaliera San Camillo Forlanini
Roma, 00152
Recruiting
Irccs Istituto Clinico Humanitas
Rozzano, 20089
Recruiting
I.R.C.C.S. Casa Sollievo Della Sofferenza
San Giovanni Rotondo, 71013
Recruiting
Centro Ricerche Cliniche Di Verona
Verona, 37134
Recruiting

Other trials in Italy

Japan17 sites, 17 recruiting

Hyogo Cancer Center
Akashi-shi, 673-8558
Recruiting
Chiba Cancer Center
Chiba, 260-8717
Recruiting
National Cancer Center Hospital
Chūōku, 104-0045
Not yet recruiting
Nho Kyushu Cancer Center
Fukuoka, 811-1395
Recruiting
Saitama Medical University International Medical Center
Hidaka-shi, 350-1298
Recruiting
National Cancer Center Hospital East
Kashiwa-shi, 277-8577
Recruiting
St. Marianna University Hospital
Kawasaki-shi, 216-8511
Not yet recruiting
Kagawa University Hospital
Kita-gun, 761-0793
Recruiting
Saitama Cancer Center
Kitaadachi-gun, 362-0806
Not yet recruiting
Kobe City Hospital Organization Kobe City Medical Center General Hospital
Kobe, 650-0047
Recruiting
Cancer Institute Hospital of Jfcr
Kōtoku, 135-8550
Recruiting
Kurashiki Central Hospital
Kurashiki-shi, 710-8602
Not yet recruiting
Kochi Medical School Hospital
Nankoku-shi, 783-8505
Recruiting
Osaka International Cancer Institute
Osaka, 541-8567
Recruiting
Shizuoka Cancer Center
Shizuoka, 411-8777
Recruiting
The University of Osaka Hospital
Suita-shi, 565-0871
Recruiting
Kanagawa Cancer Center
Yokohama, 241-8515
Recruiting

Other trials in Japan

Spain17 sites, 17 recruiting

Hospital Universitari Germans Trias I Pujol
Badalona, 08916
Not yet recruiting
Hospital General Universitario Vall D Hebron
Barcelona, 08035
Not yet recruiting
Hospital Clinic Barcelona Main
Barcelona, 08036
Not yet recruiting
Hospital de La Santa Creu I Sant Pau
Barcelona, 08041
Not yet recruiting
Complejo Hospitalario Universitario Insular-Materno Infantil
Las Palmas de Gran Canaria, 35016
Not yet recruiting
Hospital General Universitario Gregorio Maranon
Madrid, 28007
Not yet recruiting
Hospital Universitario Fundacion Jimenez Diaz
Madrid, 28040
Not yet recruiting
Hospital Universitario 12 de Octubre
Madrid, 28041
Not yet recruiting
Hospital Universitario Puerta de Hierro de Majadahonda
Majadahonda, 28220
Not yet recruiting
Son Espases University Hospital
Palma de Mallorca, 07120
Not yet recruiting
Hospital Universitario de Navarra
Pamplona, 31008
Not yet recruiting
Hospital Universitario Quironsalud Madrid
Pozuelo de Alarcón, 28223
Not yet recruiting
Hospital Universitario Marques de Valdecilla
Santander, 39012
Not yet recruiting
Hospital Universitari Mutua de Terrassa
Terrassa, 08221
Not yet recruiting
Instituto Valenciano de Oncologia
Valencia, 46009
Not yet recruiting
Hospital Clinico Universitario de Valencia
Valencia, 46010
Not yet recruiting
Hospital Universitario Miguel Servet
Zaragoza, 50009
Not yet recruiting

Other trials in Spain

Brazil16 sites, 16 recruiting

Fundacao Pio Xii Hospital de Cancer de Barretos
Barretos, 14784400
Not yet recruiting
Centro de Pesquisas Clinica Reichow
Blumenau, 89010-340
Recruiting
Hospital Erasto Gaertner - Liga Paranaense de Combate Ao Cancer
Curitiba, 81520-060
Not yet recruiting
Oncosite - Centro de Pesquisa Clinica E Oncologia
Ijuí, 98700-500
Not yet recruiting
Clinica de Neoplasias Litoral Ltda
Itajaí, 88301-220
Recruiting
Hospital Bruno Born
Lajeado, 95900-000
Not yet recruiting
Liga Norte-Rio-Grandense Contra O Câncer
Natal, 59062-000
Recruiting
Hospital de Clinicas de Porto Alegre
Porto Alegre, 90035-903
Not yet recruiting
Irmandade Da Santa Casa de Misericordia de Porto Alegre
Porto Alegre, 90050-170
Recruiting
Hgb - Hospital Giovanni Battista - Mae de Deus Center
Porto Alegre, 90110-270
Recruiting
Hospital Moinhos de Vento
Porto Alegre, 90560032
Not yet recruiting
Hospital Das Clínicas Fmrp-Usp
Ribeirão Preto, 14051-140
Not yet recruiting
Nob - Nucleo de Oncologia Da Bahia
Salvador, 40170-110
Not yet recruiting
Ceon Pesquisas
São Caetano do Sul, 09541-270
Recruiting
Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto
SAO JOSE RIO Preto, 15090-000
Recruiting
Icavc - Instituto Do Câncer Arnaldo Vieira de Carvalho
São Paulo, 01221-020
Not yet recruiting

Other trials in Brazil

Australia15 sites, 15 recruiting

Box Hill Hospital
Box Hill, Victoria, 03128
Recruiting
The Canberra Hospital
Canberra, 02605
Not yet recruiting
Austin Hospital
Heidelberg, Victoria, 03084
Recruiting
Icon Cancer Centre Kurralta Park
Kurralta Park, South Australia, 05037
Recruiting
Peter Maccallum Cancer Centre
Melbourne, Victoria, 03000
Recruiting
The Alfred Hospital
Melbourne, Victoria, 03004
Recruiting
Fiona Stanley Hospital
Murdoch, 06150
Recruiting
Port Macquarie Base Hospital
Port Macquarie, New South Wales, 02444
Recruiting
Prince of Wales Hospital Au
Randwick, New South Wales, 02031
Recruiting
Gold Coast University Hospital
Southport, Queensland, 04215
Recruiting
Townsville Cancer Centre
Townsville, Queensland, 04814
Recruiting
Calvary Mater Newcastle
Waratah, New South Wales, 02298
Recruiting
Westmead Hospital
Westmead, New South Wales, 02046
Recruiting
Wollongong Hospital
Wollongong, New South Wales, 02500
Recruiting
Princess Alexandra Hospital Australia
Woolloongabba, Queensland, 04102
Recruiting

Other trials in Australia

Georgia14 sites, 14 recruiting

High Technology Hospital Medcenter
Batumi, 06004
Recruiting
Jsc Evex Hospitals
Kutaisi, 04600
Recruiting
Aversi Clinic Ltd
Marneuli, 03000
Recruiting
Archangel St. Michael Multi Profile Clinical Hospital
Tbilisi, 00102
Not yet recruiting
Israel-Georgian Medical Research Clinic Helsicore
Tbilisi, 00112
Recruiting
Todua Clinic, Llc
Tbilisi, 00112
Recruiting
Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic, Llc
Tbilisi, 00144
Recruiting
Institute of Clinical Oncology Ltd
Tbilisi, 00159
Recruiting
K. Eristavi National Center of Experimental and Clinical Surgery
Tbilisi, 00159
Recruiting
Tim-Tbilisi Institute of Medicine Ltd
Tbilisi, 00160
Not yet recruiting
Cancer Research Center Ltd
Tbilisi, 00177
Not yet recruiting
Caucasus Medical Centre Llc
Tbilisi, 00186
Recruiting
Innova Llc
Tbilisi, 00186
Not yet recruiting
Medulla Chemotherapy and Immunotherapy Clinic
Tbilisi, 00186
Recruiting

Other trials in Georgia

Germany14 sites, 14 recruiting

Charite - Campus Virchow-Klinikum
Berlin, 13353
Recruiting
University Hospital Carl Gustav Carus
Dresden, 01307
Not yet recruiting
Universitaetsklinikum Essen
Essen, 45147
Not yet recruiting
Krankenhaus Nordwest Gmbh
Frankfurt am Main, 60488
Recruiting
University Medical Center Freiburg
Freiburg im Breisgau, 79106
Not yet recruiting
University Medical Centre Hamburg-Eppendorf Centre of Oncology
Hamburg, 20246
Recruiting
Asklepios Klinik Altona
Hamburg, 22763
Recruiting
Hannover Medical School
Hanover, 30625
Recruiting
Uksh Campus Lubeck
Lübeck, 23538
Not yet recruiting
Klinikum Der University Munchen - Campus Grosshadern
München, 81377
Not yet recruiting
Klinikum Neuperlach
München, 81737
Recruiting
Roche Diagnostics Gmbh
Penzberg, 82377
Recruiting
Universitaetsklinikum Regensburg
Regensburg, 93053
Recruiting
Universitatkinikums Ulm
Ulm, 89081
Not yet recruiting

Other trials in Germany

South Korea14 sites, 14 recruiting

Samsung Changwon Hospital
Changwon-si, 51353
Recruiting
National Cancer Center
Goyang-si, 10408
Recruiting
Seoul National University Bundang Hospital
Seongnam, 13620
Recruiting
Cha Bundang Medical Center
Seongnam-si, 13496
Recruiting
Korea University Anam Hospital
Seoul, 02841
Recruiting
Seoul National University Hospital
Seoul, 03080
Recruiting
Kangbuk Samsung Hospital
Seoul, 03181
Recruiting
The Catholic University of Korea, Eunpyeong St. Mary'S Hospital
Seoul, 03312
Recruiting
Severance Hospital Yonsei University Health System
Seoul, 03722
Recruiting
Hanyang University Seoul Hospital
Seoul, 04763
Recruiting
Asan Medical Center
Seoul, 05505
Recruiting
Samsung Medical Center
Seoul, 06351
Not yet recruiting
The Catholic University of Korea Seoul St. Mary'S Hospital
Seoul, 06591
Recruiting
Ajou University Hospital
Suwon, 16499
Recruiting

Other trials in South Korea

Argentina11 sites, 11 recruiting

Hospital Britanico de Buenos Aires
Buenos Aires, 01280
Not yet recruiting
Investigaciones Clinicas Moleculares Icm
Buenos Aires, 01425
Recruiting
Centro Medico Austral
Ciudad Autonoma Buenos Aires, 01019
Not yet recruiting
Instituto Medico Especializado Alexander Fleming
Ciudad Autonoma Buenos Aires, 01426
Not yet recruiting
Hospital Italiano de Buenos Aires
Ciudad Autonoma Buenos Aires, C1199ABB
Not yet recruiting
Instituto de Investigaciones Clinicas Cordoba S.A.
Córdoba, X5000AAW
Not yet recruiting
Hospital Privado Centro Medico de Cordoba S.A
Córdoba, X5016KEH
Not yet recruiting
Centro Oncologico Riojano Integral (Cori)
La Rioja, 05300
Recruiting
Investigaciones Oncologicas C Colon
Mar del Plata, 07600
Not yet recruiting
Instituto de Oncologia de Rosario
Rosario, S2000KZE
Recruiting
Exelsus Srl
San Miguel de Tucumán, T4000IAN
Not yet recruiting

Other trials in Argentina

United Kingdom9 sites, 9 recruiting

Bristol Haematology and Oncology Centre
Bristol, BS2 8ED
Recruiting
Velindre Cancer Centre
Cardiff, CF14 2TL
Not yet recruiting
St James University Hospital
Leeds, LS9 7TF
Recruiting
Barts Hospital
London, EC1A 7BE
Recruiting
Guys Hospital
London, SE1 9RT
Recruiting
Royal Marsden Hospital - Fulham
London, SW3 6JJ
Recruiting
Kent Oncology Centre - Maidstone Hospital
Maidstone, ME16 9QQ
Recruiting
The Christie Nhs Foundation Trust Uk
Manchester, M20 4BX
Recruiting
The Royal Marsden Nhs Foundation Trust - Sutton
Sutton, SM2 5PT
Recruiting

Other trials in United Kingdom

Canada8 sites, 8 recruiting

Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2
Not yet recruiting
Cisss de La Monteregie Centre
Greenfield Park, Quebec, J4V 2H1
Not yet recruiting
Juravinski Cancer Clinic
Hamilton, Ontario, L8V5C2
Not yet recruiting
Hotel-Dieu de Levis
Lévis, Quebec, G6V 3Z1
Recruiting
Unite de Recherche Clinique Cisss Des Laurentides
Saint-Jérôme, Quebec, J7Z 2V4
Not yet recruiting
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, S7N 4H4
Not yet recruiting
Sunnybrook Research Institute
Toronto, Ontario, M4N 3M5
Not yet recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9
Recruiting

Other trials in Canada

France8 sites, 8 recruiting

Institut de Cancerologie de L'Ouest
Angers, 49055
Not yet recruiting
Chu Bordeaux-Hopital Pellegrin
Bordeaux, 33076
Recruiting
Hôpital de La Timone
Marseille, 13385
Recruiting
Hospital Universitaire Pitie-Salpetriere
Paris, 75013
Recruiting
Hospital de La Miletrie
Poitiers, 86021
Recruiting
Chu de Reims
Reims, 51100
Recruiting
University Hospital of Saint Etienne
Saint-Etienne, 42055
Recruiting
Chu Toulouse Hopital Rangueil
Toulouse, 31059
Recruiting

Other trials in France

Belgium7 sites, 7 recruiting

C.H.U. Brugmann - Site Victor Horta
Brussels, 01020
Not yet recruiting
Universitair Ziekenhuis Brussel
Brussels, 01090
Recruiting
Cliniques Universitaires Ucl Saint-Luc
Brussels, 01200
Recruiting
Universitair Ziekenhuis Antwerpen (Uza)
Edegem, 02650
Recruiting
Universitair Ziekenhuis Gent (Uz Gent)
Ghent, 09000
Recruiting
Universitaire Ziekenhuis Leuven - Gasthuisberg
Leuven, 03000
Recruiting
Chu Ucl Namur University Hospital Mont-Godinne
Yvoir, 05530
Recruiting

Other trials in Belgium

Denmark4 sites, 4 recruiting

Aalborg Universitetshospital
Aalborg, 09100
Recruiting
OUH
Odense C, 05000
Recruiting
Sjaellands Universitetshospital
Roskilde, 04000
Not yet recruiting
Sygehus Lillebælt - Vejle
Vejle, 07100
Recruiting

Other trials in Denmark

Netherlands4 sites, 4 recruiting

Meander Medisch Centrum
Amersfoort, 3818 TZ
Recruiting
Martini Ziekenhuis
Groningen, 9728 NT
Recruiting
Maastricht Umc+
Maastricht, 6229 HX
Recruiting
Erasmus Medical Center
Rotterdam, 3015 GD
Not yet recruiting

Other trials in Netherlands

Norway4 sites, 4 recruiting

Haukeland Universitetssjukehus
Bergen, 05021
Recruiting
Akershus Universitetssykehus Hf
Lørenskog, 01478
Recruiting
Utprovingsenheten, Oslo University Hospital Radiumhospitalet
Oslo, 00379
Recruiting
Universitetssykehuset I Trondheim - St. Olavs Hospital
Trondheim, 07030
Not yet recruiting

Other trials in Norway

Poland4 sites, 4 recruiting

Wojewodzkie Centrum Szpitalne Kotliny Jeleniogorskiej
Jelenia Góra, 58-506
Not yet recruiting
Mazowiecki Szpital Wojewodzki Im. SW. Jana Pawla Ii W Siedlcach Sp Z O O
Siedlce, 08-110
Not yet recruiting
Luxmed Onkologia Sp. Z O.O.
Warsaw, 01-748
Not yet recruiting
Narodowy Instytut Onkologii Im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy
Warsaw, 02-034
Not yet recruiting

Other trials in Poland

Austria3 sites, 3 recruiting

Lkh - Universitaetsklinikum Graz
Graz, 08036
Recruiting
Ordensklinikum Krankenhaus Der Barmherzigen Schwestern Linz
Linz, 04010
Recruiting
Lkh - Universitatsklinikum Der Pmu Salzburg
Salzburg, 05020
Recruiting

Other trials in Austria

Switzerland3 sites, 3 recruiting

Inselspital - Universitaetsspital Bern
Bern, 03010
Not yet recruiting
Chuv, Lausanne University Hospital
Lausanne, 01005
Not yet recruiting
Hoch Health Ostschweiz
Sankt Gallen, 09007
Not yet recruiting

Other trials in Switzerland

Puerto Rico1 site, 1 recruiting

Pan American Center For Oncology Trials Llc Dorado Office
Dorado, 00646
Recruiting

Other trials in Puerto Rico

About this study

Official title: A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Conditions: CRC (Colorectal Cancer)
Being tested: INCA33890, Placebo, Bevacizumab, FOLFOX
Keywords: Metastatic Colorectal Cancer, Colon Cancer, INCA33890
Medical subject headings: Colorectal Neoplasms, Colonic Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

INCA33890Drug
INCA33890 will be administered at protocol defined dose.
PlaceboDrug
Placebo will be administered at protocol defined dose.
BevacizumabDrug
Bevacizumab will be administered at protocol defined dose.
FOLFOXDrug
FOLFOX will be administered at protocol defined dose.

Study groups in NCT07284849
Study group	Role	What they receive
INCA33890	Experimental	INCA33890 will be administered in combination with bevacizumab and FOLFOX at the protocol-defined dose. Receives: Drug: INCA33890; Drug: Bevacizumab; Drug: FOLFOX
Placebo	Placebo comparator	Placebo will be administered in combination with bevacizumab and FOLFOX at the protocol-defined dose. Receives: Drug: Placebo; Drug: Bevacizumab; Drug: FOLFOX

What is being measured

The primary outcome is the main question the study is designed to answer.

Progression-Free Survival (PFS)
Defined as the time from the date of randomization to the date of the first documented progression as determined by the investigator per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 or death due to any cause.
Measured: Up to 3 years

Secondary outcomes (8)

Overall Survival (OS)
Defined as the time from the date of randomization to the date of death due to any cause.
Measured: Up to 4 years
Objective response
Defined as complete response (CR) or partial response (PR) as determined by the investigator per RECIST v1.1.
Measured: Up to 3 years
Duration of Response (DOR)
Defined as the time from the earliest date of documented response until the earliest date of disease progression as determined by the investigator per RECIST v1.1 or death due to any cause, whichever occurs first.
Measured: Up to 3 years
Treatment Emergent Adverse Events (TEAEs)
Adverse events reported for the first time or worsening of a pre-existing event after first dose of study treatment, up to 90 days after the last dose INCA33890/placebo (or 30 days after the last dose of any FOLFOX component or bevacizumab if later) or the start of new anticancer therapy, whichever comes first.
Measured: Up to 4 years
TEAEs leading to dose interruptions, dose reductions or discontinuation of study treatmen
TEAEs leading to dose interruption or study drug discontinuation.
Measured: Up to 4 years
Change from baseline in EQ-5D-5L score at protocol-defined visits
The EQ-5D-5L is a validated, self-reported instrument for assessing HRQoL across 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 response levels of severity, ranging from no problems to extreme problems. The questionnaire also includes a visual analog scale for self-rated overall health on a scale from 0 (worst imaginable health) to 100 (best imaginable health).
Measured: Up to 4 years
Change from baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-Core 30 (C30) at protocol-defined visits
The EORTC QLQ-C30 is a validated, self-administered questionnaire developed to assess the quality of life in cancer patients. It consists of 30 questions divided into several subscales, including 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, nausea and vomiting, and pain), a global health status/QoL scale, and a number of single-item measures that assess additional symptoms such as dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties.
Measured: Up to 4 years
Change from baseline in Functional Assessment of Cancer Therapy Colorectal Symptom Index (FCSI)-9 score at protocol-defined visits
The FCSI-9 is a 9-item questionnaire derived from the FACT-C questionnaire to be a briefer, more targeted symptom-specific measure for patients with CRC. The FCSI-9 assesses common symptoms of CRC, including energy, pain, weight loss, nausea, diarrhea, swelling or cramps in the stomach area, appetite, ability to enjoy life, and overall quality of life. The questionnaire is scored to produce a single total score, with a higher score indicating less symptoms.
Measured: Up to 4 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

5 Mar 202628 Sep 2029

First posted16 Dec 2025
Study start5 Mar 2026
Primary completion29 Dec 2028 (estimated)
Study completion28 Sep 2029 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for CRC (Colorectal Cancer)Studies of the same condition, open and under way.
More trials run by Incyte CorporationThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 3
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind
Who is masked: Participant, Care provider, Investigator, Outcomes assessor
Enrolment: 700 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07284849
Sponsor's protocol ID: INCA033890-303
Other IDs: 2025-523735-19-00, 2025
Status last verified: Oct 2026
First submitted: 9 Dec 2025
Last updated: 30 Oct 2026
Results posted: No
Data monitoring committee: Yes
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: Yes: Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Interested in taking part?

Incyte Corporation Call Center (US)

1.855.463.3463

medinfo@incyte.com

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See sites and contacts

Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 2
Tislelizumab in People With Colorectal Cancer
Colorectal Cancer
Not yet recruitingPhase 2
Alberta Cancer Exercise Dose in Colorectal Cancer
Cancer, Colorectal Cancer

All CRC (Colorectal Cancer) trials

Study at a glance

From the registry record, last updated by the sponsor on 30 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
ClinicalTrials.gov ID: NCT07284849
Acronym / sponsor ID: INCA033890-303
Conditions: CRC (Colorectal Cancer)
Keywords: Metastatic Colorectal Cancer, Colon Cancer, INCA33890
Phase: Phase 3
Study type: Interventional
Recruitment status: Recruiting
Enrolment: 700 participants (estimated)
Lead sponsor: Incyte CorporationIndustry (pharma, biotech, devices)
Study start: 5 Mar 2026 (actual)
Primary completion: 29 Dec 2028 (estimated)
Study completion: 28 Sep 2029 (estimated)
First posted: 16 Dec 2025 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind (participant, care provider, investigator, outcomes assessor)
Number of arms: 2

Arm	Type	Receives
INCA33890	Experimental	Drug: INCA33890, Drug: Bevacizumab, Drug: FOLFOXINCA33890 will be administered in combination with bevacizumab and FOLFOX at the protocol-defined dose.
Placebo	Placebo comparator	Drug: Placebo, Drug: Bevacizumab, Drug: FOLFOXPlacebo will be administered in combination with bevacizumab and FOLFOX at the protocol-defined dose.

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (5 listed)

Stage IV colorectal adenocarcinoma not amenable to curative resection.
No prior systemic treatment for unresectable or metastatic disease. Participants who received adjuvant or neoadjuvant therapy may enroll if there was no recurrence within 12 months of the end of treatment.
Measurable disease per RECIST v1.1.
ECOG performance status of 0 or 1.
Adequate organ function determined by laboratory results.

Key exclusion criteria (9 listed)

MSI-H/dMMR per historical data in the medical record.
BRAF V600E mutation per historical data in the medical record.
Untreated and/or progressing CNS metastases.
History of other malignancy within 2 years.
Treatment with an anti-PD-(L)1 or other immune checkpoint inhibitor for any indication within the last 3 years.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
INCA33890INCA33890 will be administered at protocol defined dose.	Drug	INCA33890
PlaceboPlacebo will be administered at protocol defined dose.	Drug	Placebo
BevacizumabBevacizumab will be administered at protocol defined dose.	Drug	INCA33890, Placebo
FOLFOXFOLFOX will be administered at protocol defined dose.	Drug	INCA33890, Placebo

Primary outcome

Progression-Free Survival (PFS)
Time frame: Up to 3 years
Defined as the time from the date of randomization to the date of the first documented progression as determined by the investigator per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 or death due to any cause.

8 secondary outcomes

Overall Survival (OS)
Time frame: Up to 4 years
Objective response
Time frame: Up to 3 years
Duration of Response (DOR)
Time frame: Up to 3 years
Treatment Emergent Adverse Events (TEAEs)
Time frame: Up to 4 years
TEAEs leading to dose interruptions, dose reductions or discontinuation of study treatmen
Time frame: Up to 4 years
Change from baseline in EQ-5D-5L score at protocol-defined visits
Time frame: Up to 4 years
Change from baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-Core 30 (C30) at protocol-defined visits
Time frame: Up to 4 years
Change from baseline in Functional Assessment of Cancer Therapy Colorectal Symptom Index (FCSI)-9 score at protocol-defined visits
Time frame: Up to 4 years

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 30 Oct 2026.
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal CancerLink provided by the sponsor.
Individual participant dataSharing planned: Yes. Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Related trials for CRC (Colorectal Cancer)

Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 2
Tislelizumab in People With Colorectal Cancer
Colorectal Cancer
Not yet recruitingPhase 2
Alberta Cancer Exercise Dose in Colorectal Cancer
Cancer, Colorectal Cancer

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.

Incyte Corporation Call Center (US) contact

1.855.463.3463

medinfo@incyte.com

Incyte Corporation Call Center (ex-US) contact

+800 00027423

eumedinfo@incyte.com

Incyte Medical Monitor study director

Incyte Corporation

297 sites in 22 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing INCA33890, Bevacizumab and FOLFOX in people with CRC (Colorectal Cancer), run by Incyte Corporation at 297 sites in 22 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 30 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 297 sites in United States, China, Italy, Japan, Spain and 17 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Incyte Corporation Call Center (US) (1.855.463.3463, medinfo@incyte.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Progression-Free Survival (PFS) (time frame: Up to 3 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07284849.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Oct 2026.